{"entity":{"id":"nct07099430","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.","aka":[],"tldr":"A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. is a phase 1/2 interventional study registered as NCT07099430 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2025-09-05. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-024 for Injection and Toripalimab Injection.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07099430","url":"https://clinicaltrials.gov/study/NCT07099430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["opamtistomig"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07099430","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07099430/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"opamtistomig","kind":"drug","name":"Opamtistomig","route":"/drugs/opamtistomig/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}